ICPT - インタ―セプト・ファ―マシュ―ティカルズ （Intercept Pharmaceuticals Inc.）ICPTのニュース
Drug pricing watchdog raises alarm over upcoming liver disease meds 2023/05/29 19:00:00 Seeking Alpha
The influential U.S. drug pricing watchdog ICER has warned about cost of future NASH drugs from Madrigal Pharma (MDGL) and Intercept Pharma (ICPT). Read more here.
Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target Cut to $14.00 by Analysts at Bank of America 2023/05/24 08:10:41 The AM Reporter
Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) had its target price decreased by Bank of America from $17.00 to $14.00 in a research note published on Tuesday morning, The Fly reports. A number of other research analysts have also weighed in on ICPT. Royal Bank of Canada upped their price objective on Intercept Pharmaceuticals from $17.00 […]
The Rising Challenge for Intercept Pharmaceuticals: Analyst Downgrade Amid Ocaliva''s DILI Concerns 2023/05/23 18:53:39 Benzinga
Canaccord Genuity has lowered the price target for Intercept Pharmaceutical Inc (NASDAQ: ICPT ) from $26 to $12, with a Hold rating . The analyst says Ocaliva, for PBC, is worth $16 per share, with OCA in NASH costing $4 based on overhead allocation for the rest of 2023 as it sees the program winding down. The FDA has concerns about drug-induced liver injury (DILI) that could be fatal. Related: What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept''s ''OCA In NASH … Full story available on Benzinga.com
Intercept Pharma Slips 28% As FDA Panel Votes Against Liver Disease Drug 2023/05/22 20:43:21 EIN News Pharmaceuticals
Intercept Pharmaceutics , Inc (ICPT) shares are down … . The FDA''s Gastrointestinal Drugs Advisory Committee (GIDAC) voted 12 …
Intercept crashes 29% after FDA AdCom snub for liver disease therapy 2023/05/22 17:42:11 Seeking Alpha
Intercept Pharma (ICPT) fell ~28% Monday after a group of independent experts at the FDA declined to endorse its liver disease drug obeticholic acid. Read more here.
Intercept cuts debt further with deal to exchange convertible debt (NASDAQ:ICPT) 2022/09/02 12:15:00 Seeking Alpha
Intercept Pharmaceuticals (ICPT), a biotech focused on liver diseases, announced privately negotiated exchange agreements on Friday to repurchase nearly $44.5M worth of convertible debt…
Intercept Pharmaceuticals Inc. (ICPT): Why Is The Stock Strong? 2022/08/31 12:00:00 Marketing Sentinel
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) has a beta value of 1.26 and has seen 1.52 million shares traded in the last trading session. The company, currently valued at $509.08M, closed the last trade at $16.28 per share which meant it lost -$2.3 on the day or -12.38% during that session. The ICPT stock price is -30.53% … Intercept Pharmaceuticals Inc. (ICPT): Why Is The Stock Strong? Read More »
Intercept Pharmaceuticals Inc. (ICPT) is an excellent investment, but the stock is overvalued/undervalued right now 2022/08/29 13:16:00 US Post News
A share of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) closed at $18.02 per share on Friday, down from $18.91 day before. While Intercept Pharmaceuticals Inc. has underperformed by -4.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ICPT rose by 34.48%, with highs and lows ranging from $21.25 […]
Intercept Pharmaceuticals PT Lowered to $28 at B.Riley 2022/08/22 12:02:01 Investing.com
https://www.investing.com/news/pro/intercept-pharmaceuticals-pt-lowered-to-28-at-briley-432SI-2877438
Intercept Pharmaceuticals Settles Ocaliva Patent Litigation Case, With Dr Reddy''s 2022/08/19 07:02:06 Goodreturns
Intercept Pharmaceuticals Inc has said it entered into a settlement agreement with Dr Reddy''s Laboratories resolving the previously disclosed patent litigation to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets in the USA. Ocaliva is
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva for PBC Outside the U.S. 2022/07/01 20:01:00 Wallstreet:Online
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on May 5, 2022, has now closed. As a result of this transaction, Intercept’s
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S. 2022/07/01 20:01:00 GlobeNewswire
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on May 5, 2022, has now closed. As a result of this transaction, Intercept’s international business has been divested and its international commercial and medical infrastructure have transitioned to Advanz Pharma.
Given A -64.9% Drop From High, Can Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) Quickly Recover? 2022/06/25 13:00:00 Marketing Sentinel
During the last session, Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s traded shares were 0.76 million, with the beta value of the company hitting 1.44. At the end of the trading day, the stock’s price was $13.56, reflecting an intraday gain of 0.22% or $0.03. The 52-week high for the ICPT share is $22.36, that puts it down … Given A -64.9% Drop From High, Can Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) Quickly Recover? Read More »
Intercept Announces PBC Data Presentations at The International Liver Congress 2022 2022/06/21 11:30:00 Wallstreet:Online
MORRISTOWN, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts highlighting the benefits of obeticholic acid (OCA) in individuals with primary biliary cholangitis (PBC) will be
Intercept Pharmaceuticals Inc. (ICPT): Significant Improvements, Worth Being Considered 2022/06/11 12:30:00 Stocks Register
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) concluded the trading at $12.68 on Friday, June 10, with a fall of -4.88% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $13.33 and 5Y monthly beta was reading 1.35 with its price kept floating in the … Intercept Pharmaceuticals Inc. (ICPT): Significant Improvements, Worth Being Considered Read More »